on Catheter Precision, Inc
Catheter Precision, Inc. Reports Q2 2024 Highlights
FORT MILL, SC / ACCESSWIRE / August 14, 2024 / Catheter Precision, Inc. (NYSE American: VTAK) released its Q2 2024 financials and operational report. The MedTech company, known for its innovations in cardiac electrophysiology, highlighted significant milestones, including first commercial sales of LockeT in the US and new clinical hires.
The firm reported that more US hospitals than projected have shown interest, with 23 hospitals evaluating LockeT and 10 assessing VIVO products. Internationally, a major VIVO evaluation began in Italy. Catheter Precision also completed the VIVO EU Registry and published new research on LockeT in a leading journal.
Financially, total assets at June 30, 2024, were $26 million, with total revenues for the quarter at $93,000. However, the company faced a net loss of $4.2 million for Q2. CEO David Jenkins emphasized the focus on talent acquisition and the initial revenue generation from LockeT.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Catheter Precision, Inc news